SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining traction as a crypto embodying cannabis culture, community, and freedom. Community members emphasize its focus on positivity, long-term vision, and real-world applications within the cannabis space. The conversation highlights Weedcoin as more than just a token, but as a movement for culture and community.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics is trending due to recent Phase 3 trial data for their skin drug, Sonelokimab, which showed mixed results. While one trial succeeded, another was impacted by a high placebo response, leading to community discussion around potential regulatory implications and future prospects. Community members are actively debating the approvability of the drug, potential buyout scenarios, and comparing it to competitors in the sector.

JFB Construction Holdings is a commercial and residential real estate construction and development company, which engages in delivering services to commercial and residential markets. It operates through the following segments: Commercial Construction, Residential Construction, and Real Estate Development. The Commercial Construction segment includes all activities related to the construction of commercial properties. The Residential Construction segment focuses on the construction of residential properties including single-family homes and multi-family units. The Real Estate Development segment refers to the acquisition, development, and sale of real estate properties. The company was founded by Joseph F. Basille III on April 9, 2024 and is headquartered in Lantana, FL.

JFB Construction Holdings - Ordinary Shares - Class A

JFB is trending due to a recently announced private placement, with the community actively discussing whether the stock can sustain its momentum. Some traders believe the financing deal could be dilutive, while others are optimistic about a potential short squeeze given the tight float. Overall, traders are closely monitoring JFB for potential continuation or pullback.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics ($AVTX) is trending due to recent surges in volume and price, sparking speculation about a potential short squeeze or upcoming news catalyst. Community discussions revolve around the possibility of significant upside, comparing it to similar stocks with low floats, while also referencing analyst upgrades and price target increases. The stock's volatility and potential for further gains are key talking points.

Advisorshares Trust - AdvisorShares MSOS 2x Daily ETF

AdvisorShares MSOS Daily Leveraged ETF

MSOX is trending as investors discuss potential catalysts for cannabis stocks, including possible rescheduling and Trump's stance on the industry. Community members are weighing the risks and potential rewards, with some anticipating significant gains while others remain cautious due to the sector's volatility. Bullish sentiment seems to be building amid speculation of upcoming news and a possible short squeeze.

Trulieve Cannabis Corp. engages in the provision of medical cannabis products and services. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Quincy, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis

Trulieve Cannabis is trending as community members discuss the potential impact of cannabis rescheduling following supportive comments from former President Trump. Investors are weighing potential benefits like tax relief and uplisting to major exchanges against the risk of political delays. Community members are closely watching for further developments and anticipating a potential surge in the stock price.

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Merus N.V

Merus is trending following news of Genmab's acquisition of the company for $8 billion, or $97 per share, sparking excitement among biotech investors. The community is buzzing about the buyout price and potential implications for other companies in the sector. Some investors are expressing regret for selling their shares earlier, while others are drawing comparisons to similar acquisitions.

Green Thumb Industries, Inc. engages in the manufacture and distribution of branded cannabis products. Its brands include RYTHM, Dogwalkers, Beboe, Good Green, Doctor Solomon’s, and &Shine. It operates through the Retail and Consumer Packaged Goods segments. The Retail segment focuses on retailing cannabis to patients and consumers. The Consumer Packaged Goods segment refers to the cultivation, production, and sale of cannabis products to retail stores. The company was founded by Benjamin Kovler and Max Cohen on February 18, 2002 and is headquartered in Chicago, IL.

Green Thumb Industries Inc - Ordinary Shares (Sub Voting)

Green Thumb Industries

Green Thumb Industries is trending as the community discusses the potential impact of cannabis rescheduling following Trump's recent comments and a new $50 million share repurchase program. Community talking points include tax relief, increased profitability for US cannabis companies, and advantages over Canadian competitors. Some investors view GTBIF as a strong, profitable US-based company poised to benefit from regulatory changes.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as traders weigh the potential impacts of a looming government shutdown and speculate on its effects on the market, particularly regarding the release of upcoming jobs data. Community discussions revolve around potential market reactions, with some anticipating a bullish outcome if a shutdown is averted, while others are bracing for volatility and a possible downturn, especially given concerns about high stock valuations and AI-driven market dynamics.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is trending as traders anticipate updates from the company's nomlabofusp clinical development program for Friedreich's ataxia, expected to be released with a conference call. Community discussions revolve around the potential for positive clinical outcomes and speculation regarding leaked data, with some noting unusual options activity and potential for a significant price swing. Bullish sentiment seems to be building.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now?

As precision oncology advances, Tempus and Illumina lead the way with innovation. Which stock shows stronger growth momentum now?

Here's Why Illumina (ILMN) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Tempus AI Enhances Cancer Research Tools With FDA-Cleared xR IVD

TEM secures FDA clearance for its xR IVD device, advancing RNA-based cancer research and precision medicine tools.

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025 

GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.

ILMN Stock to Gain From the Launch of Illumina Protein Prep Assay

The Illumina Protein Prep rollout boosts multiomics, strengthens disease insights and supports ILMN stock momentum.

CRISPR Therapeutics (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound?

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term

TMO Receives FDA Approval for Oncomine Dx Target Test

Thermo Fisher secures FDA approval for its Oncomine Dx Target Test to identify NSCLC patients eligible for HERNEXEOS treatment.

KMDA vs. ILMN: Which Stock Is the Better Value Option?

Illumina (ILMN) Reliance on International Sales: What Investors Need to Know

Evaluate Illumina's (ILMN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Illumina Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

ILMN
Illumina Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ILMN News

ILMN Illumina Inc